Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

Stopped Institutional constraints due to research staffing and diminished data safety monitoring infrastructure

Conditions

• Stage III Non-small-cell Lung Cancer

Interventions

• DRUG: Durvalumab

Sponsor

Rush University Medical Center

Collaborators

• [object Object]